Targeting the CCR5 receptor: a promising approach for HIV

Combination therapy with chemokine receptor 5 (CCR5) antagonists, maraviroc or vicriviroc, provides potent virological suppression, and appears to be well tolerated, in patients with HIV infection, according to results of two studies presented at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention [Sydney, Australia; July 2007]. A further two studies presented at this conference showed promising results for PRO 140 and INCB9471, two more CCR5 antagonists, in the treatment of such patients.